Heparin
- Generic Name
- Heparin
- Brand Names
- Heparin Leo
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- T2410KM04A
- Background
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...
- Indication
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...
- Associated Conditions
- Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
- Associated Therapies
- Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices
Heparin Solution and INTEM/HEPTEM Analysis
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2013-08-29
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT01522846
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seonnam, Gyounggi, Korea, Republic of
Effect of Increased Free Fatty Acids on Leptin Function
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT01520454
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2015-05-13
- Target Recruit Count
- 1829
- Registration Number
- NCT01519518
- Locations
- 🇬🇧
Liverpool Heart and Chest Hospital, Liverpool, Merseyside, United Kingdom
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT01516814
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT01516840
Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Clinica Mediterranea
- Target Recruit Count
- 837
- Registration Number
- NCT01465503
- Locations
- 🇮🇹
IRCCS Policlinico Multimedica, Milan, Italy
🇮🇹Clinica Mediterranea, Naples, Italy
Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 260
- Registration Number
- NCT01464671
- Locations
- 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
The Effect of Heparin on Inhalation Injury
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Tehran University of Medical Sciences
- Registration Number
- NCT01454869
- Locations
- 🇮🇷
Shahid Mothary Burn Hospital, Tehran, Iran, Islamic Republic of
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4068
- Registration Number
- NCT01444612
Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
- Conditions
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- Alberta Children's Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT01343680
- Locations
- 🇨🇦
Stollery Children's Hospital, Edmonton, Alberta, Canada
🇨🇦Alberta Children's Hospital, Calgary, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.